Teus van Laar Selected Research

Apomorphine

10/2021	Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
1/2021	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
1/2020	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries.
11/2018	Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases.
1/2018	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
12/2017	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
12/2016	The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
12/2016	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
2/2016	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
1/2016	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Teus van Laar Research Topics

Disease

53	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2003
6	Dementia (Dementias) 01/2022 - 12/2004
6	Dyskinesias (Dyskinesia) 10/2021 - 04/2008
5	Hallucinations (Hallucination) 06/2018 - 09/2009
4	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2004
3	Cognitive Dysfunction 01/2022 - 12/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2019
2	Dystonia (Limb Dystonia) 12/2016 - 09/2015
1	Lewy Body Disease (Lewy Body Dementia) 01/2021
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2020
1	Inflammation (Inflammations) 06/2020
1	Fatigue 01/2020
1	Retinal Degeneration 01/2019
1	Glaucoma 01/2019
1	Ganglion Cysts (Ganglion) 01/2019
1	Movement Disorders (Movement Disorder) 01/2019
1	Drug-Related Side Effects and Adverse Reactions 11/2018
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 11/2018
1	Schizophrenia (Dementia Praecox) 06/2018
1	Essential Tremor (Essential Tremors) 02/2018
1	Orthostatic Hypotension (Postural Hypotension) 12/2017
1	REM Sleep Behavior Disorder 10/2017
1	Anosmia 10/2017
1	Glycogen Storage Disease Type VI (Glycogenosis Type VI) 12/2016
1	Hereditary Spastic Paraplegia 06/2015
1	Polyneuropathies (Polyneuropathy) 05/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 05/2013
1	Infections 02/2011
1	Fibrosis (Cirrhosis) 01/2009
1	Disease Progression 04/2008
1	Sialorrhea 12/2007
1	Parkinsonian Disorders (Parkinsonism) 12/2007
1	Nausea 12/2004
1	Tremor (Tremors) 12/2004
1	Vomiting 12/2004

Drug/Important Bio-Agent (IBA)

14	Apomorphine FDA Link 10/2021 - 09/2009
14	Levodopa (L Dopa)FDA LinkGeneric 10/2021 - 01/2003
9	Cholinergic Agents (Cholinergics)IBA 01/2022 - 12/2004
5	Pharmaceutical PreparationsIBA 01/2022 - 12/2004
5	Carbidopa (Lodosyn)FDA LinkGeneric 01/2020 - 02/2011
4	Rivastigmine (Exelon)FDA LinkGeneric 01/2014 - 12/2004
3	Dopamine Agonists (Dopamine Agonist)IBA 01/2022 - 01/2003
3	Biomarkers (Surrogate Marker)IBA 06/2020 - 10/2017
2	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 04/2008
2	Glucose (Dextrose)FDA LinkGeneric 11/2020 - 01/2020
2	fluoroethoxy-benzovesamicolIBA 06/2020 - 01/2019
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 10/2011 - 08/2010
2	Dopamine Receptors (Dopamine Receptor)IBA 04/2008 - 01/2003
2	Dopamine Agents (Dopaminergic Agents)IBA 04/2008 - 01/2003
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2022
1	fluorodopa F 18IBA 06/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020
1	Retinaldehyde (Retinal)IBA 01/2019
1	sodium metabisulfite (sodium pyrosulfite)IBA 11/2018
1	KetanserinIBA 06/2018
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 06/2018
1	Antihypertensive Agents (Antihypertensives)IBA 06/2018
1	Serotonin (5 Hydroxytryptamine)IBA 06/2018
1	Clozapine (Clozaril)FDA LinkGeneric 06/2018
1	hydroxide ionIBA 12/2017
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 10/2017
1	Baclofen FDA LinkGeneric 06/2015
1	SolventsIBA 06/2015
1	EndotoxinsIBA 11/2014
1	Coffee FDA Link 01/2014
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 05/2013
1	levodopa drug combination carbidopa (Nakom)FDA LinkGeneric 02/2011
1	Monoamine Oxidase (MAO)IBA 01/2010
1	rasagiline (Azilect)FDA Link 01/2010
1	Pergolide (Permax)FDA Link 01/2009
1	HomocysteineIBA 08/2008

Therapy/Procedure

14	Therapeutics 01/2022 - 04/2008
12	Deep Brain Stimulation 01/2022 - 12/2008
2	Subcutaneous Infusions 01/2018 - 01/2010
2	Activities of Daily Living (ADL) 01/2014 - 12/2004
1	Denervation 01/2021
1	Cognitive Training 01/2020
1	Dry Powder Inhalers 01/2019
1	Contraindications 01/2019
1	Transcranial Magnetic Stimulation 06/2018
1	Injections 12/2016
1	Home Nursing (Nursing, Home) 01/2012
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 02/2011
1	Radiotherapy 12/2007